RUBINSTEIN JULIE sold $948K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.60 ($25.66–$30.53, $0.95M total) across 6 trades over 2026-10-06 to 2026-10-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider activity record and can influence short-term sentiment, but it does not introduce new guidance, trial results, or corporate actions.
Market read
Traders may briefly reassess ADPT sentiment due to insider selling, but the 10b5-1 structure makes the fundamental read-through weaker.
What to watch
Traders may over-interpret insider sales; the key incremental signal is the sale size and timing, not any new company fundamentals.
Background
The filing is an SEC Form 4 insider transaction for Adaptive Biotechnologies, reported by President and COO Julie Rubinstein.
Ticker impact
Adaptive Biotechnologies insider sale: President and COO Julie Rubinstein sold $948,223 of ADPT stock via a 10b5-1 plan across 6 trades (Oct 6-8).
Likely mild near-term pressure or volatility as traders weigh insider selling, but the 10b5-1 framing reduces signal strength.
Form 4 provides exact sale size, dates, and that it was pre-arranged under Rule 10b5-1; without accompanying operational or guidance changes, the news is unlikely to drive a sustained repricing.
Market effects
Limited spillover to biotech peers; this is company-specific insider selling with no stated sector catalyst.
None expected beyond ADPT-specific sentiment.
None expected.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerAdaptive Biotechnologies Corp
US-listed biotech company whose insider sale is disclosed on Form 4.
- insiderJulie Rubinstein
President and COO who sold ADPT shares via an open-market transaction under a 10b5-1 plan.
